Lurbinectedin is a drug used for the treatment of certain types of cancer. It is currently undergoing clinical trials to evaluate its efficacy in treating various types of cancer. One ongoing clinical trial for Lurbinectedin is NCT02454972 [2]. This phase II study is evaluating the safety and efficacy of Lurbinectedin in treating patients with small cell lung cancer. The study is expected to be completed in 2021. Another clinical trial for Lurbinectedin is C82382 [3]. This phase I/II study is evaluating the safety and efficacy of Lurbinectedin in treating patients with advanced solid tumors. The study is currently recruiting participants and is expected to be completed in 2022. These clinical trials will provide valuable information about the safety and efficacy of Lurbinectedin and may lead to its approval for the treatment of cancer.

Sources:
[2] https://clinicaltrials.gov/ct2/show/NCT02454972
[3] https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c82382